Swiss BioQuant — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Swiss BioQuant is a well-established, privately-held bioanalytical CRO offering critical method development, validation, and sample analysis services to drug developers. Its core expertise lies in LC-MS/MS for small molecules and ligand-binding assays (e.g., ELISA) for large molecules, with recent expansion into qPCR for cell and gene therapy bioanalysis. The company is GLP-certified by Swissmedic and serves as an outsourcing partner for pharmaceutical and biotech companies, supporting programs from discovery through clinical trials. With over 20 years of collective experience, it emphasizes quality, regulatory compliance, and state-of-the-art instrumentation.

DiagnosticsProteomics

Technology Platform

Dual-platform bioanalytical services: 1) LC-MS/MS for small molecules, metabolites, and biomarkers. 2) Ligand-binding assays (e.g., ELISA) for large molecules (proteins, antibodies). Expanded with qPCR for cell and gene therapy bioanalysis.

Opportunities

Growth is driven by the expanding market for outsourced bioanalytical services, particularly for complex large molecules and new modalities.

The company's recent foray into qPCR for cell and gene therapy bioanalysis positions it to capture significant demand from this rapidly growing therapeutic sector.

Risk Factors

Key risks include dependence on pharmaceutical R&D spending cycles, intense competition from larger global CROs, and the operational risk associated with maintaining stringent regulatory compliance (GLP).

Any failure in quality systems could severely damage its reputation.

Competitive Landscape

Swiss BioQuant competes in the fragmented bioanalytical CRO market against large, full-service global CROs (e.g., LabCorp, IQVIA) and many smaller niche players. Its differentiation is based on deep technical expertise in LC-MS/MS and LBA, a strong quality focus, and specialized services for cell and gene therapy within the European market.

More companies in Switzerland →